Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO II)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Pfizer
Hospira, Inc.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: February 21, 2012
Last updated: December 7, 2016
Last verified: December 2016
The purpose of this study is to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit™ (epoetin zeta) administered subcutaneously in patients with renal anaemia. The other key objective of this study is to obtain information on adverse drug reactions (ADR) associated with Retacrit™ (epoetin zeta), use of epoetin zeta during pregnancy and lactation and data on long term use.

Renal Anemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco Ii)

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence Rate of Adverse Events of Special Interest [ Time Frame: 156 weeks ] [ Designated as safety issue: Yes ]
    Ongoing routine doctor visits for 156 weeks

Secondary Outcome Measures:
  • Adverse drug reactions [ Time Frame: 156 weeks ] [ Designated as safety issue: Yes ]
    Descriptive evaluation including incidence rates of adverse drug reactions.

  • Information on treatment with Retacrit during pregnancy and lactation [ Time Frame: 156 weeks ] [ Designated as safety issue: No ]
  • Data on long term use [ Time Frame: 156 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Pre-dose serum samples

Estimated Enrollment: 4500
Study Start Date: July 2010
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Single group

Detailed Description:
This is a non-interventional, multi-centre, longitudinal observation with a defined population using a prospective cohort design to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit™ (epoetin zeta) administered subcutaneously in patients with renal anaemia.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients currently under treatment with Retacrit (epoetin zeta) administered subcutaneously for renal anaemia.

Inclusion Criteria:

  • Patients currently under treatment with Retacrit™ (epoetin zeta) administered subcutaneously for renal anaemia.
  • Informed consent given in writing after being provided with detailed information about the characteristics of this observation by the physician.
  • Patients expected to be available for 3 years of observation

Exclusion Criteria:

  • Any contraindications as per the current Summary of Product Characteristics (SPC) of Retacrit™
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01543477

Contact: Pfizer Call Center 1-800-718-1021

  Show 178 Study Locations
Sponsors and Collaborators
Hospira, Inc.
Study Director: Pfizer Call Center Pfizer
  More Information

Responsible Party: Pfizer Identifier: NCT01543477     History of Changes
Other Study ID Numbers: EPOE-09-11  C1111006 
Study First Received: February 21, 2012
Last Updated: December 7, 2016
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Finland: Finnish Medicines Agency
France: Conseil National de l'Ordre des Médecins
France: The Commission nationale de l’informatique et des libertés
Germany: Federal Institute for Drugs and Medical Devices
Ireland: Irish Medicines Board
Italy: The Italian Medicines Agency
Portugal: National Pharmacy and Medicines Institute
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
Bulgaria: Bulgarian Drug Agency
Greece: National Organization of Medicines
Croatia: Agency for Medicinal Product and Medical Devices
Denmark: Danish Health and Medicines Authority

Additional relevant MeSH terms:
Hematologic Diseases processed this record on December 08, 2016